Supplementary material to:

Real-Life Data on Treatment and Outcomes in Advanced Ovarian Cancer: An Observational Multinational Cohort Study (RESPONSE Trial)

Marth C, Abreu MH, Andersen KK, et al.

SUPPLEMENTARY TABLE 1. Effect of bevacizumab on overall survival and progression-free survival, adjusting for confounders

Confounder	HR	Lower 95% confidence limit	Upper 95% confidence limit	*P* value
Bevacizumab effect on OS	0.62	0.42	0.91	0.01
Bevacizumab effect on PFS	1.03	0.82	1.30	0.79
BRCAm effect on OS	0.69	0.35	1.35	0.28
BRCAm effect on PFS	0.60	0.41	0.84	<0.01

Abbreviations: BRCAm, *BRCA1* and/or *BRCA2* mutation; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.

All analyses are adjusted by age (continuous and linear), country, stage, and indication of good prognosis, defined as primary surgery and no visual residual disease.

SUPPLEMENTARY FIGURE 1. Patients (n) by year of diagnosis (index date)